WHO ICTRP trial
A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded…
PACTR202307901658960 · Pan African Clinical Trials Registry (PACTR) · Not Recruiting
Key facts
| Trial ID | PACTR202307901658960 |
|---|---|
| Public title | A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar. |
| Scientific title | A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar. |
| Primary sponsor | International Vaccine Institute |
| Registry | Pan African Clinical Trials Registry (PACTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase-1 |
| Countries | Burkina Faso;Madagascar |
| Conditions | Schistosomiasis |
| Registration date | Oct 2, 2023 |
| Target size | 120 |
| Registry page | pactr.samrc.ac.za |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: